Synthesis, Characterization, and In Vitro Anticancer Evaluation of Novel 2,5-Disubstituted 1,3,4-Oxadiazole Analogue

Table 1

Sixty human tumor cell lines anticancer screening data of 1,3,4-oxadiazole analogue.

Panel/cell line	Growth percent in one dose assay
Compound; (NSC code)	7; (776963)	17; (776964)	18; (776965)	20; (776966)	21; (776967)	22; (776968)	24; (776969)	27; (776971)	38; (776970)	40; (776973)	42; (776972)
Leukemia
CCRF-CEM	62.29	97.80	18.96	96.39	97.48	95.05	96.04	0.73	22.17	88.72	91.95
HL-60(TB)	62.07	84.99	27.06	93.94	87.64	92.65	84.86	18.17	70.13	100.01	94.79
K-562	57.10	96.88	30.83	94.02	89.08	73.62	74.44	−3.18	24.16	86.70	92.41
MOLT-4	38.52	93.82	57.10	81.63	98.55	84.81	82.67	−13.79	58.84	80.98	80.79
RPMI-8226	46.61	103.90	15.32	90.25	105.14	99.66	91.19	−4.32	62.44	82.45	94.31
SR	43.32	100.48	31.61	79.12	108.64	92.79	86.39	−7.63	NT	75.27	85.97
Non-small cell lung cancer
A549/ATC	68.28	102.26	83.29	99.50	101.27	100.60	103.01	81.28	82.82	88.52	100.80
HOP-62	75.35	94.46	82.64	93.91	99.00	91.48	94.50	49.80	74.55	92.66	87.05
HOP-92	48.46	101.70	76.22	93.69	99.25	96.45	101.84	14.22	29.71	65.04	73.35
NCI-H226	71.75	105.00	85.35	92.81	99.06	88.51	95.88	64.92	71.42	81.09	92.83
NCI-H23	75.93	93.51	74.68	92.88	98.68	87.99	94.37	66.54	72.86	86.03	87.52
NCI-H322M	93.43	106.90	92.29	85.97	107.44	NT	NT	92.32	78.67	88.95	107.35
NCI-H460	85.87	107.30	92.22	104.87	109.52	105.19	104.90	94.15	97.77	95.26	102.46
NCI-H522	63.25	100.15	71.20	83.30	89.60	102.67	95.45	70.22	75.33	90.31	96.41
Colon Cancer
COLO 205	80.21	105.24	64.37	97.14	104.48	98.73	97.24	84.59	88.67	92.43	102.20
HCC-2998	85.93	99.22	78.89	105.11	101.20	98.41	99.35	64.49	91.02	99.13	102.31
HCT-116	52.32	98.66	7.52	86.71	107.15	88.92	93.41	−2.01	22.22	76.72	93.59
HCT-15	62.63	99.53	48.99	99.71	106.48	100.05	94.38	17.48	59.61	82.78	93.26
HT29	69.34	110.21	57.87	103.09	106.76	116.20	102.94	4.53	87.36	77.61	104.15
KM12	75.93	102.58	77.76	99.64	101.47	101.95	102.29	16.75	78.55	87.48	96.72
SW-620	88.64	110.90	44.97	108.56	111.64	104.62	105.48	18.07	35.64	94.63	105.16
CNS cancer
SF-268	63.84	100.31	78.44	100.92	105.11	98.48	97.26	20.56	79.10	95.00	101.65
SF-295	76.15	101.14	99.71	100.44	101.59	104.07	103.01	92.01	99.41	97.56	99.73
SF-539	92.51	105.21	80.83	98.30	93.04	93.80	104.84	63.34	78.31	89.57	95.69
SNB-19	81.62	99.60	85.99	104.39	106.66	107.24	118.35	52.42	86.69	100.65	102.12
SNB-75	58.53	80.69	69.28	70.05	73.22	70.69	79.63	54.90	51.42	68.98	65.12
U251	82.46	103.79	72.36	98.35	97.23	91.91	98.31	42.97	71.06	88.68	97.88
Melanoma
LOX IMVI	63.23	93.92	35.03	97.46	94.55	87.02	94.83	19.62	67.22	88.33	85.77
MALME-3M	77.64	91.22	55.80	95.90	93.74	99.30	92.28	72.49	98.95	123.55	99.75
M14	82.44	99.10	65.84	104.89	99.12	101.29	103.24	45.50	83.29	97.31	98.93
MDA-MB-435	70.53	104.12	52.86	100.61	104.79	104.95	102.28	50.75	90.57	100.57	101.98
SK-MEL-2	92.34	108.70	78.37	101.15	92.57	113.85	112.61	89.78	87.92	91.80	103.20
SK-MEL-28	112.94	112.37	101.46	115.05	107.29	116.40	116.82	90.94	107.52	110.01	104.89
SK-MEL-5	62.94	103.93	56.83	102.49	100.93	99.16	100.67	80.51	95.51	99.00	98.47
UACC-257	83.64	105.12	79.98	113.86	107.46	108.60	111.79	94.56	99.85	105.57	99.76
UACC-62	59.62	95.76	47.86	85.07	96.49	95.85	107.63	50.78	66.60	72.73	75.35
Ovarian cancer
IGROV1	76.24	113.11	65.98	83.58	104.80	111.13	132.21	37.80	68.88	73.42	76.86
OVCAR-3	49.61	106.56	69.55	113.21	111.72	100.92	107.68	35.71	88.39	94.52	105.76
OVCAR-4	50.34	95.67	61.34	82.18	97.13	86.48	103.76	53.88	72.53	71.06	82.16
OVCAR-5	106.83	94.49	120.39	114.36	100.24	103.17	120.08	87.66	96.39	96.96	94.41
OVCAR-8	70.89	101.90	57.81	103.22	107.61	95.51	99.33	25.47	76.36	90.40	96.99
NCI/ADR-RES	62.13	101.99	89.85	93.91	103.13	90.74	95.32	34.60	68.12	85.72	94.68
SK-OV-3	90.18	3 97.22	92.78	91.03	97.60	88.65	103.94	77.34	81.98	87.32	89.99
Renal cancer
786-0	40.52	98.54	58.27	93.10	99.88	93.03	100.61	62.73	70.97	90.18	93.77
A498	57.65	110.18	105.94	107.33	95.15	78.05	99.26	54.08	60.34	65.84	96.42
ACHN	78.17	106.04	65.89	94.78	109.02	105.23	103.76	49.86	74.96	88.72	92.40
RXF 393	75.91	111.91	76.07	101.43	109.85	103.21	105.90	60.28	87.66	91.37	98.87
SN12C	73.98	95.38	74.05	109.91	105.74	100.61	NT	29.44	86.85	91.91	91.68
TK-10	85.06	114.13	111.84	168.13	96.89	104.18	94.72	77.13	106.65	136.93	140.07
UO-31	34.06	66.38	39.98	58.38	75.50	68.36	71.08	8.45	23.47	52.19	54.46
Prostate cancer
PC-3	58.32	96.94	65.48	82.75	98.08	90.66	86.35	46.23	71.58	76.86	83.03
DU-145	58.80	119.29	71.06	107.46	108.55	97.39	106.30	63.49	99.19	98.06	116.21
Breast cancer
MCF7	50.02	93.06	20.47	59.04	91.23	91.22	88.77	11.59	39.72	84.08	85.66
MDA-MB-231/ATCC	54.03	96.65	79.63	91.54	120.58	104.47	105.94	47.68	61.51	78.25	71.62
HS 578T	79.72	110.45	90.07	104.25	132.59	89.18	100.48	72.43	86.82	93.19	97.10
BT-549	73.60	93.87	48.94	92.07	91.04	86.09	95.84	14.67	83.85	93.88	91.31
T-47D	25.58	86.17	42.22	78.22	95.06	86.86	93.64	48.89	55.68	74.73	82.45
MDA-MB-468	36.56	110.38	53.93	90.74	102.81	102.12	103.17	92.11	95.67	96.62	109.56
Mean	68.21	100.70	66.23	96.41	100.99	96.26	99.33	46.61	73.77	88.86	94.16
Delta	42.63	34.32	58.71	38.03	27.77	27.90	28.25	64.78	51.60	36.67	39.70
Range	87.36	52.91	112.87	109.75	59.37	48.04	61.13	112.73	85.35	84.74	85.61